Acute biochemical effects of growth hormone treatment compared with conventional treatment in familial hypophosphataemic rickets.

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Conventional treatment of familial hypophosphaiaemic rickets with oral phosphate and 1 alpha-hydroxycholecalciferol (1 alpha HCC) does not satisfactorily correct the metabolic or physical defects of the disease and can have adverse effects, such as nephrocalcinosis.

Who Took Part

The abstract describes 6 children taking part.

PubMed indexes the participants as young children, children and teenagers, both men and women.

The researchers have assessed the acute effects of GH on phosphate and calcium metabolism in 6 children (age 4-14 years) with familial hypophosphataemic rickets.

What Was Measured

The subject headings attached to it are Calcitriol, Calcium, Glomerular Filtration Rate, Growth Hormone, Hydroxycholecalciferols, Hypophosphatemia, Familial and Kidney Tubules.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 6 children.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1996 (Clinical endocrinology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.